Literature DB >> 28906581

Is there a benefit of mechanical thrombectomy in patients with large stroke (DWI-ASPECTS ≤ 5)?

P-F Manceau1, S Soize1, M Gawlitza1, G Fabre1, S Bakchine2, C Durot1, I Serre2, G-E Metaxas1, L Pierot1.   

Abstract

BACKGROUND AND
PURPOSE: Whether to withhold mechanical thrombectomy when the diffusion-weighted imaging (DWI) lesion exceeds a given volume is undetermined. Our aim was to identify markers that will help to select patients with large DWI lesions [DWI-Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) ≤ 5] that may benefit from thrombectomy.
METHODS: From May 2010 to November 2016, 82 acute ischaemic stroke patients with DWI-ASPECTS ≤5 (43 men, 64.6 ± 14.4 years, National Institutes of Health Stroke Scale 18.4 ± 5.4) treated with state-of-the-art mechanical thrombectomy were studied. Thrombectomy alone was performed in 28 (34%) and bridging therapy in 54 (66%) patients. Recanalization was defined as a thrombolysis in cerebral infarction score 2B-3 and significant hemorrhagic transformation as parenchymal haematoma type 2 (European Cooperative Acute Stroke Study 3 classification). Pretreatment variables were compared between patients with a good (modified Rankin Scale 0-2) and a poor (modified Rankin Scale 3-6) neurological outcome at 3 months.
RESULTS: Overall, 28 patients (34%) achieved good neurological outcome at 3 months. Recanalizers were significantly more likely to achieve good outcome (61% vs. 7.3%, P < 0.0001), had lower mortality (24% vs. 49%, P = 0.03) and similar rates of parenchymal haematoma type 2 (9.8% vs. 7.3%, P = 1) compared to non-recanalizers. Regression modelling identified DWI-ASPECTS >2 [odds ratio (OR) 6.93; 95% confidence interval (CI) 1.05-45.76, P = 0.04), glycaemia ≤6.8 mmol/l (OR 4.05; 95% CI 1.09-15.0, P = 0.03) and thrombolysis (OR 3.67; 95% CI 1.04-12.9, P = 0.04) as independent predictors of good neurological outcome.
CONCLUSIONS: In patients with DWI-ASPECTS ≤5, two-thirds of patients experienced good neurological outcome when recanalized by state-of-the-art thrombectomy, whilst only one in 14 non-recanalizers achieved similar outcomes. Pretreatment markers of good neurological outcomes were DWI-ASPECTS >2, intravenous thrombolysis and glycaemia ≤6.8 mmol/l.
© 2017 EAN.

Entities:  

Keywords:  diffusion-weighted imaging; magnetic resonance imaging; stroke; thrombectomy

Mesh:

Substances:

Year:  2017        PMID: 28906581     DOI: 10.1111/ene.13460

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

1.  Noncontrast CT versus Perfusion-Based Core Estimation in Large Vessel Occlusion: The Blood Pressure after Endovascular Stroke Therapy Study.

Authors:  James E Siegler; Steven R Messé; Heidi Sucharew; Scott E Kasner; Tapan Mehta; Niraj Arora; Amy K Starosciak; Felipe De Los Rios La Rosa; Natasha R Barnhill; Akshitkumar M Mistry; Kishan Patel; Salman Assad; Amjad Tarboosh; Katarina Dakay; Jeff Wagner; Alicia Bennett; Bharathi Jagadeesan; Christopher Streib; Stewart A Weber; Rohan Chitale; John J Volpi; Stephan A Mayer; Shadi Yaghi; Mahesh V Jayaraman; Pooja Khatri; Eva A Mistry
Journal:  J Neuroimaging       Date:  2019-11-24       Impact factor: 2.486

2.  DWI-Based Algorithm to Predict Disability in Patients Treated with Thrombectomy for Acute Stroke.

Authors:  H Raoult; M V Lassalle; B Parat; C Rousseau; F Eugène; S Vannier; S Evain; A Le Bras; T Ronziere; J C Ferre; J Y Gauvrit; B Laviolle
Journal:  AJNR Am J Neuroradiol       Date:  2020-01-30       Impact factor: 3.825

Review 3.  Neurological Functional Independence After Endovascular Thrombectomy and Different Imaging Modalities for Large Infarct Core Assessment : A Systematic Review and Meta-analysis.

Authors:  Jian Wang; Jianting Qiu; Yujie Wang
Journal:  Clin Neuroradiol       Date:  2022-08-03       Impact factor: 3.156

4.  Dose reference levels and clinical determinants in stroke neuroradiology interventions.

Authors:  Jad Farah; Aymeric Rouchaud; Theophraste Henry; Catherine Regen; Cristian Mihalea; Jacques Moret; Laurent Spelle
Journal:  Eur Radiol       Date:  2018-07-17       Impact factor: 5.315

Review 5.  Acute Ischemic Stroke: Acute Management and Selection for Endovascular Therapy.

Authors:  Sabeen Dhand; Paul O'Connor; Charles Hughes; Shao-Pow Lin
Journal:  Semin Intervent Radiol       Date:  2020-05-14       Impact factor: 1.513

6.  A Simple Imaging Guide for Endovascular Thrombectomy in Acute Ischemic Stroke: From Time Window to Perfusion Mismatch and Beyond.

Authors:  Wengui Yu; Wei-Jian Jiang
Journal:  Front Neurol       Date:  2019-05-24       Impact factor: 4.003

Review 7.  Acute ischemic stroke patients with diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Score ≤ 5 can benefit from endovascular treatment: a single-center experience and literature review.

Authors:  Kangping Song; Min Guan; Wenxian Li; Zhen Jing; Xiaomei Xie; Changzheng Shi; Jianye Liang; Hongyu Qiao; Li'an Huang
Journal:  Neuroradiology       Date:  2019-02-06       Impact factor: 2.804

Review 8.  Recanalization Therapy for Acute Ischemic Stroke with Large Vessel Occlusion: Where We Are and What Comes Next?

Authors:  Mohammad Shafie; Wengui Yu
Journal:  Transl Stroke Res       Date:  2021-01-06       Impact factor: 6.829

9.  Mechanical Thrombectomy in Anterior Circulation Occlusion Could Be More Effective than Medical Management Even in Low DWI-ASPECTS Patients.

Authors:  Tsuyoshi Ohta; Masanori Morimoto; Kenji Okada; Maki Fukuda; Hirokazu Onishi; Noritaka Masahira; Toshiki Matsuoka; Takaya Tsuno; Mitsuhiro Takemura
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

10.  Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel Occlusion with Large Ischemic Core (RESCUE-Japan LIMIT): Rationale and Study Protocol.

Authors:  Shinichi Yoshimura; Kazutaka Uchida; Nobuyuki Sakai; Hiroshi Yamagami; Manabu Inoue; Kazunori Toyoda; Yuji Matsumaru; Yasushi Matsumoto; Kazumi Kimura; Reiichi Ishikura; Takeshi Morimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-12-24       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.